Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

European Journal of Neuroscience

Volumn 15, Issue 1, 2002, Pages 120-132

  Lundblad, M ^a   Andersson, M ^a   Winkler, C ^a,b   Kirik, D ^a   Wierup, N ^a   Cenci Nilsson, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Circling; Movement disorders; Preclinical; Stereotypies; Turning

Indexed keywords

5 METHOXY 5 N,N DIMETHYLTRYPTAMINE; AMANTADINE; BROMOCRIPTINE; CLOZAPINE; LEVODOPA; NALOXONE; OXIDOPAMINE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; YOHIMBINE;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; FEMALE; FORELIMB; INVOLUNTARY MOVEMENT; MOTOR ACTIVITY; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; TASK PERFORMANCE; VALIDATION PROCESS;

ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BROMOCRIPTINE; DYSKINESIA, DRUG-INDUCED; FEMALE; GAIT; LEVODOPA; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; STEREOTYPED BEHAVIOR; SYMPATHOLYTICS;

EID: 0036459952     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816x.2001.01843.x     Document Type: Article

References (63)

1. Andersson, M., Hilbertson, A. & Cenci, M.A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis., 6, 461-474.
2. 3)H]spiperone binding. Brain Res., 379, 294-299.
3. Bennett, J.P., Landow, E.R. & Schuh, L.A. (1993) Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology, 43, 1551-1555.
4. Bezard, E., Brotchie, J.M. & Gross, C.E. (2001) Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nature Rev. Neurosci., 2, 577-588.
5. Blanchet, P.J., Konitsiotis, S. & Chase, T.N. (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disorders, 13, 798-802.
6. Brotchie, J.M., Henry, B., Hille, C.J. & Crossman, A.R. (1998) Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. In Fahn, S., Marsden, C.D. & DeLong, M.R. (eds), Advances in Neurology, Dystonia 3. Lippincott-Raven Publishers, Philadelphia, PA, pp 41-52.
7. Carey, R.J. (1991a) Chronic L-DOPA treatment in the unilateral 6-OHDA rat: Evidence for behavioral sensitization and biochemical tolerance. Brain Res., 568, 205-214.
8. Carey, R.J. (1991b) Naloxone reverses L-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci., 48, 1303- 1308.
9. Cenci, M.A., Lee, C.S. & Björklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706
10. Chesler, E.J. & Salamone, J.D. (1996) Effects of acute and repeated clozapine injections on cholinomimetic- induced vacuous jaw movements. Pharmacol. Biochem. Behav., 54, 619-624.
11. Choi-Lundberg, D.L., Lin, Q., Schallert, T., Crippens, D., Davidson, B.L., Chang, Y.N., Chiang, Y.L., Qian, J., Bardwaj, L. & Bohn, M.C. (1998) Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol., 154, 261-275.
12. Creese, I. & Iversen, S.D. (1973) Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res., 55, 369-382.
13. Doucet, J.-P., Nakabeppu, Y., Bédard, P.J., Hope, B.T., Nestler, E.J., Jasmin, B.J., Chen, J.-S., Iadarola, M.J., St-Jean, M., Wigle, N., Blanchet, P., Grondin, R. & Robertson, G.S. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta-FosB-like proteins in both the rodent and primate striatum. Eur. J. Neurosci., 8, 365-381
14. Dunnett, S.B. & Robbins, T.W. (1992) The functional role of mesotelencephalic dopamine systems. Biol. Rev. Camb. Philos. Soc., 67, 491-518.
15. Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A.M. & Agid, Y. (1997) Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology, 48, 658-662.
16. Gomez-Mancilla, B. & Bédard, P.J. (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP- treated monkeys. Clin. Neuropharmacol., 16, 418-427.
17. Grondin, R., Doan, V.D., Gregoire, L. & Bédard, P.J. (1999) D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology, 52, 771-776.
18. Grondin, R., Hadj Tahar, A., Doan, V.D., Ladure, P. & Bédard, P.J. (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch. Pharmacol., 361, 181-186.
19. Hagell, P. & Widner, H. (1999) Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale. Mov. Disord., 14, 448-455
20. Henry, B., Crossman, A.R. & Brotchie, J.M. (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 151, 334-342.
21. Henry, B., Fox, S.H., Peggs, D., Crossman, A.R. & Brotchie, J.M. (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord., 14, 744-753.
22. Herman, J.-P. & Abrous, D. (1994) Dopaminergic neural grafts after fifteen years; results and perspectives. Progr. Neurobiol., 44, 1-35.
23. Johansson, P.A., Andersson, M., Andersson, K.E. & Cenci, M.A. (2001) Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis., 8, 220-239
24. Kirik, D., Rosenblad, C. & Björklund, A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol., 152, 259-277.
25. Kirik, D., Rosenblad, C., Bjorklund, A. & Mandel, R.J. (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci., 20, 4686- 4700.
26. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N. & Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290, 767-773.
27. Lee, C.S., Cenci, M.A., Schulzer, M. & Bjorklund, A. (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain, 123, 1365-1379.
28. Lee, C.S., Sauer, H. & Bjorklund, A. (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience, 72, 641-653
29. Lees, A.J. & Stern, G.M. (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 44, 1020-1023.
30. Lindner, M.D., Plone, M.A., Francis, J.M. & Emerich, D.F. (1996) Validation of a rodent model of Parkinson's Disease: Evidence of a therapeutic window for oral Sinemet. Brain Res. Bull., 39, 367-372.
31. Lindvall, O. (1997) Neural transplantation: A hope for patients with Parkinson's disease. Neuroreport, 8, iii-x.
32. Luginger, E., Wenning, G.K., Bosch, S. & Poewe, W. (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord., 15, 873-878.
33. Mandel, R.J., Rendahl, K.G., Spratt, S.K., Snyder, R.O., Cohen, L.K. & Leff, S.E. (1998) Characterization of intrastriatal recombinant adeno-associated virus- mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci., 18, 4271-4284.
34. Mandel, R.J., Spratt, S.K., Snyder, R.O. & Leff, S.E. (1997) Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl Acad. Sci. USA, 94, 14083-14088.
35. Manson, A.J., Iakovidou, E. & Lees, A.J. (2000) Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord., 15, 336-337.
36. Menon, M.K., Clark, W.G. & Fleming, R.M. (1973) Blockade of the central effects of d-amphetamine sulfate by amantadine hydrochloride. Eur. J. Pharmacol., 21, 311-317.
37. Miller, R. & Beninger, R.J. (1991) On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol., 36, 229-256
38. Montoya, C.P., Campbell-Hope, L.J., Pemberton, K.D. & Dunnett, S.B. (1991) The 'staircase test': A measure of independent forelimb reaching and grasping abilities in rats. J. Neurosci. Meth., 36, 219-228.
39. Murray, A.M. & Waddington, J.L. (1990) The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: Behavioural indices. Eur. J. Pharmacol., 186, 79-86.
40. Nutt, J.G. (1990) Levodopa-induced dyskinesia: Review, observations and speculations. Neurology, 40, 340-345.
41. Olsson, M., Nikkhah, G., Bentlage, C. & Björklund, A. (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci., 15, 3863-3875.
42. Pearce, R.K., Banerji, T., Jenner, P. & Marsden, C.D. (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord., 13, 234-241
43. Piccini, P., Weeks, R.A. & Brooks, D.J. (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol., 42, 720-726
44. Rascol, O., Arnulf, I., Peyro-Saint Paul, H., Brefel-Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A.M., Descombes, S., Bejjani, B., Fabre, N., Montastruc, J.L. & Agid, Y. (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord., 16, 708-713.
45. Rascol, O., Brefel-Courbon, C., Descombes, S. & Montastruc, J.L. (1999) Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients. Adv. Neurol., 80, 485-490.
46. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E. & Lang, A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med., 342, 1484-1491.
47. Rascol, A., Guiraud, B., Montastruc, J.L., David, J. & Clanet, M. (1979) Long-term treatment of Parkinson's disease with bromocriptine. J. Neurol. Neurosurg. Psychiatry, 42, 143-150.
48. Rozas, G., Guerra, M.J. & Labandeira-Garcia, J.L. (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protoc, 2, 75- 84.
49. Sandyk, R. & Snider, S.R. (1986) Naloxone treatment of l-dopa-induced dyskinesias in Parkinson's disease. Am. J. Psychiatry, 143, 118.
50. Sauer, H. & Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 59, 401-415.
51. Schallert, T. (1995) Models of neurological defects and defects in neurological models. Behav. Brain Sci., 18, 68-69.
52. Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. & Bland, S.T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39, 777-787.
53. Schallert, T. & Tillerson, J.L. (2000) Intervention strategies for degeneration of dopamine neurons in parkinsonism: Optimizing behavioral assessment of outcome. In Emerich, D.F., Dean, R.L. III & Sanberg, P.R. (eds), Central Nervous System Diseases: Innovative Models of CNS Diseases from Molecule to Therapy. Humana Press, Totowa, NJ, pp 131-51.
54. Schwarting, R.K.W. & Huston, J.P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol., 50, 275-331.
55. Seeman, P. (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261-284.
56. Silverman, P.B. (1992) Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat. Eur. J. Pharmacol., 229, 235-240.
57. Snow, B.J., Macdonald, L., McAuley, D. & Wallis, W. (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin. Neuropharmacol., 23, 82-85
58. Söderpalm, B. & Svensson, A.I. (1999) Naloxone reverses disinhibitory/aggressive behavior in 5,7-DHT-lesioned rats; involvement of GABA (A) receptor blockade? Neuropharmacology, 38, 1851-1859.
59. Trabucchi, M., Bassi, S. & Frattola, L. (1982) Effect of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch. Neurol., 39, 120-121.
60. Trevitt, J.T., Lyons, M., Aberman, J., Carriero, D., Finn, M. & Salamone, J.D. (1997) Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology (Berl.), 132, 74-81.
61. Ungerstedt, U. (1968) 6-Hydroxy-dopamine-induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5, 107-110.
62. Ungerstedt, U. (1976) 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome. Pharmacol. Ther. [B], 2, 37-40.
63. Ungerstedt, U. & Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal system. Brain Res., 24, 485-493.